Lyrus Life Sciences Private Limited

Lyrus Life Sciences Private Limited, incorporated on June 16, 2015, is a private unlisted pharmaceutical company based in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U24230KA2015PTC080902. As of the latest available data, Lyrus has an authorized share capital of ₹96.25 crore and a paid-up capital of ₹96.23 crore. The registered office is located at No.22, 7th Cross, Jaibharath Nagar, Bangalore, Karnataka 560033, India. The company specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

Lyrus Life Sciences operates state-of-the-art manufacturing facilities that adhere to current Good Manufacturing Practices (cGMP). These facilities are equipped with advanced technological solutions to support the development and commercialization of drug products in the global marketplace. The company's manufacturing capabilities encompass a range of dosage forms, including oral solids, liquids, dry powders for reconstitution, and dry powders in sachets, catering to both generic and specialty formulations.

The leadership team at Lyrus Life Sciences includes:

• Hemanth Kumar Bothra: Managing Director, appointed on June 16, 2015.

• Dasari Ramesh: Company Secretary, appointed on June 20, 2017.

• Leela Kanwar: Director, appointed on June 16, 2015.

Lyrus Life Sciences has established a commercial presence in key markets across Europe, Africa, Australia, the Middle East and North Africa (MENA) region, and Asia. The company focuses on developing and manufacturing pharmaceutical products that can add value to human health, with a balanced portfolio of ethical and complementary products. Lyrus offers services such as contract development and manufacturing of finished formulations, technology transfer, and R&D services.

Lyrus Life Sciences has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on developing differentiated and innovative products positions it to address the unique healthcare needs of these regions. While specific details regarding WHO prequalification are not available, the company's commitment to quality and regulatory compliance suggests potential for access to these markets.

Lyrus Life Sciences demonstrates a diversified geographic strategy by establishing a presence in multiple international markets, including Europe, Africa, Australia, MENA, and Asia. This approach mitigates concentration risk and aligns with the company's strategic direction to become a trusted partner for innovative drug delivery solutions globally. The focus on both developed and emerging markets indicates a balanced approach to growth and market penetration.

Specific details regarding Lyrus Life Sciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on developing and manufacturing pharmaceutical products suggests potential engagement with regulatory bodies, including the FDA, to ensure compliance and market access in the United States.

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates for Lyrus Life Sciences is not available, the company's adherence to cGMP standards indicates a commitment to quality manufacturing practices. The company's focus on developing and manufacturing pharmaceutical products suggests potential engagement with regulatory bodies to ensure compliance and market access in various regions.

Lyrus Life Sciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's registered office is located in Bangalore, Karnataka, indicating adherence to state drug controller approvals. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Lyrus Life Sciences. The company's adherence to cGMP standards and focus on quality manufacturing practices suggest a proactive approach to regulatory compliance.

Lyrus Life Sciences operates in a competitive pharmaceutical industry, with key competitors including Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., and Zydus Lifesciences Ltd. The company's focus on developing differentiated and innovative products, particularly in the neuropsychiatry and challenging delivery systems segments, positions it to address niche market needs and differentiate itself from competitors.

Lyrus Life Sciences' key differentiators include its state-of-the-art R&D infrastructure, a team of qualified professionals with decades of industry experience, and a focus on developing differentiated and innovative products. The company's commitment to quality manufacturing practices and adherence to cGMP standards further enhance its competitive advantage.

Lyrus Life Sciences is strategically positioned as a research and technology-driven global specialty pharmaceutical company committed to developing differentiated and innovative products. The company's focus on formulation development, exhibit and commercial manufacturing, and a balanced portfolio of generic and specialty formulations aligns with its strategic direction to become a trusted partner for innovative drug delivery solutions globally.

Lyrus Life Sciences demonstrates a strong track record in the pharmaceutical industry, with a focus on developing and manufacturing high-quality finished pharmaceutical formulations. The company's adherence to cGMP standards and commitment to quality manufacturing practices indicate reliability and consistency in its export volumes. Specific details regarding export volume and consistency are not publicly available.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's FDA facility registrations and approved ANDAs.

• WHO-GMP Certification: Verify WHO prequalification status for relevant products.

• EU GMP Certification: Ensure compliance with EU GMP standards.

• ISO Certification: Check for ISO certifications related to quality management systems.

Verification can be conducted through official regulatory bodies' websites or by contacting the company directly.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm FDA registrations, WHO prequalification, EU GMP certification, and ISO certifications.

• Assess Manufacturing Facilities: Evaluate the company's adherence to cGMP standards and inspect manufacturing facilities if possible.

• Review Financial Stability: Analyze the company's financial statements to assess stability and reliability.

• Check Export History: Review the company's export history and consistency in delivery.

• Contact References: Reach out to existing clients or partners for feedback on the company's performance.

Red flags to watch for include unresolved regulatory issues, financial instability, and negative feedback from references.

Recommended pre-order checks include verifying product quality through samples, ensuring compliance with import regulations, and confirming the company's ability to meet delivery timelines.